SciSparc Ltd SPRC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SPRC is a good fit for your portfolio.
News
-
SciSparc to Acquire AutoMax
-
SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression
-
SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research
-
SciSparc Granted Another Patent, Strengthening its Core Technology in Canada
-
SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial
-
SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure
-
SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder
-
SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe
Trading Information
- Previous Close Price
- $1.26
- Day Range
- $1.24–1.34
- 52-Week Range
- $1.15–23.66
- Bid/Ask
- $1.24 / $1.25
- Market Cap
- $3.35 Mil
- Volume/Avg
- 25,806 / 837,765
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.01
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
SciSparc Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company’s operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 3
- Website
- https://www.scisparc.com
Valuation
|
Metric
|
SPRC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 0.01 |
Price/Cash Flow | — |
Price/Earnings
SPRC
Financial Strength
|
Metric
|
SPRC
|
|---|---|
Quick Ratio | 3.41 |
Current Ratio | 4.10 |
Interest Coverage | −650.22 |
Quick Ratio
SPRC
Profitability
|
Metric
|
SPRC
|
|---|---|
Return on Assets (Normalized) | −47.49% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −65.56% |
Return on Assets
SPRC
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zyrttrjsf | Ftpw | $559.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rvssvrqp | Ywfxn | $103.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wgswvjh | Lmvqb | $103.3 Bil | |
MRNA
| Moderna Inc | Gscbdyld | Ktqgl | $48.1 Bil | |
ARGX
| argenx SE ADR | Gffzpvn | Pmkm | $23.1 Bil | |
BNTX
| BioNTech SE ADR | Lqhfbcph | Ygys | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Plhtnqgr | Jhlrld | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ryvfrhm | Hyjwpm | $15.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rxpqmbxcr | Hjygpx | $12.7 Bil | |
INCY
| Incyte Corp | Vslkkdv | Kmwwzk | $11.9 Bil |